

RESEARCH ARTICLE

Use of folic acid supplements in early pregnancy in relation to maternal plasma levels in week 18 of pregnancy

Christine Roth^{1,2}, Anne L. Bjørke-Monsen³, Ted Reichborn-Kjennerud^{1,4}, Roy M. Nilsen⁵, George D. Smith⁶, Camilla Stoltenberg^{7,8}, Pål Surén⁷, Ezra Susser^{2,9}, Per M. Ueland^{3,10}, Stein E. Vollset^{7,8} and Per Magnus^{7,11}

¹ Division of Mental Health, The Norwegian Institute of Public Health, Oslo, Norway

² Imprints Center for Genetic and Environmental Life Course Studies, Mailman School of Public Health, Columbia University, New York, NY, USA

³ Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway

⁴ Institute of Psychiatry, University of Oslo, Oslo, Norway

⁵ Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway

⁶ School of Social and Community Medicine, University of Bristol, Bristol, UK

⁷ Division of Epidemiology, The Norwegian Institute of Public Health, Oslo, Norway

⁸ Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway

⁹ New York State Psychiatric Institute, New York, NY, USA

¹⁰ Section for Pharmacology, Institute of Medicine, University of Bergen, Oslo, Norway

¹¹ The Institute of Health and Society, University of Oslo, Oslo, Norway

Scope: Birth cohorts typically measure plasma folate in midgestation, but effects of folic acid supplementation are sometimes specific to the periconceptional period. The relationship between midgestation plasma folate and periconceptional supplementation is not known. We compared plasma folate at week 18 of gestation with self-report use of supplements containing folic acid from before pregnancy to week 17 of gestation.

Methods and Results: The sample comprised 2911 women from The Norwegian Mother and Child Cohort Study. For women reporting continuous supplementation from gestational week -4 to 17 ($N = 238$), median plasma folate was 15.72 at week 18 (in nmol/L). This was about threefold higher than the median plasma folate of 5.67 for women reporting no supplementation from week -4 to 17 ($N = 844$), but only slightly higher than the median plasma folate of 13.34 for all women reporting supplementation in weeks 13–17 ($N = 1158$). Reported supplementation before week 8 was not associated with plasma folate at week 18, in an analysis that adjusted for continued supplementation after week 8.

Conclusion: Overall we found a strong and coherent relationship between self-reported folic acid use and plasma folate at week 18. We also found that plasma folate at week 18 did not reflect self-reported supplementation before week 8. For periconceptional supplementation per se, self-report data may offer a better measure.

Keywords:

Folic acid / Maternal report / Periconceptional / Plasma / Pregnancy cohort

Received: February 20, 2012

Revised: July 31, 2012

Accepted: August 13, 2012

1 Introduction

Folate is involved in cell division, cell differentiation, nucleotide synthesis, and DNA methylation and is important for fetal development [1, 2]. Maternal use of folic acid supplements has been shown to reduce the risk of having a child with neural tube defects [3–9]. For the protective effect to occur, the folic acid supplement must be taken before the neural

Correspondence: Christine Roth, Norwegian Institute of Public Health, PO Box 4404 Nydalen, N-0403, Oslo, Norway

E-mail: christine.roth@fhi.no

Fax: +47-22-35-36-05

Abbreviations: CI, confidence interval; MoBa, the Norwegian Mother and Child Cohort

tube closure around day 28. The official guideline in Norway is to take a folic acid supplement of 400 μg a day, to start a month before conceiving, and to use the supplement through the second or third month of pregnancy [10, 11]. Norway has not implemented any policy of food supplementation with folate.

With data from the Norwegian Mother and Child Cohort Study (MoBa), we recently showed that maternal use of folic acid taken before 8 wk of gestation was related to reduced risk of the child having severe language delay at the age of 3 [12]. Folic acid supplementation after week 8, however, was not related to language delay in the child at the age of 3. This suggests that the relation of folic acid intake to severe language delay could also be gestation specific.

It would have been useful to also have plasma folate levels for the period before 8 wk of gestation. Supplementation intake may be imperfectly recalled and reported [13]. In MoBa, however, the earliest time at which plasma folate could be measured was in the samples taken around week 18 (17-wk-completed gestation). This is similar to other large prospective pregnancy cohorts; the first blood sample is often collected in the second trimester [14–16].

Nonetheless, available data from MoBa offer a unique opportunity to shed light on the validity of self-report data, and examine the utility of week 18 plasma folate as an indicator of supplementation in the periconceptional period. Plasma folate at week 18 has been measured for a randomly selected subsample of participating women in MoBa, and MoBa collects remarkably detailed self-report data about maternal supplement use from before pregnancy to 17 wk of gestation. Thus, we could assess the strength and coherence of the relationship between self-reported folate supplementation and plasma folate at week 18. We could also examine the relation of maternal plasma folate at week 18 to self-reported periconceptional supplementation. We focused on supplementation use before week 8 of gestation, the interval implicated in our previous study of language delay [12].

2 Materials and methods

2.1 Study population

This study is based on MoBa, which is a prospective pregnancy cohort that has been described in detail elsewhere [17]. 108 841 pregnant women enrolled in the study during the recruitment period between 1999 and 2008, with a participation rate of 38.5% (<http://www.fhi.no/moba-en>). Written informed consent was obtained from each participant and the study was approved by the Regional Committee for Medical Research and the Norwegian Data Inspectorate.

The present analysis used a substudy of 3045 women in MoBa that has also been described in detail elsewhere [18]. Briefly, these women were a random sample of pregnant women enrolled in MoBa who gave birth during the period July 2002–December 2003, donated blood around week 18,

returned the first pregnancy questionnaire and a Food Frequency Questionnaire, and were registered in the Medical Birth Registry of Norway. Since concurrent intake of antibiotics may interfere with microbiological assays and falsely reduce plasma levels of folate to extremely low levels [19], we excluded samples with plasma folate levels less than 2.33 nmol/L ($n = 30$, i.e. the lower one percentile). We also excluded 106 samples from pregnancies that led to twins or triplets. The remaining 2911 pregnancies were used in this analysis.

2.2 Variables

Information on dietary supplement use was collected using the first pregnancy questionnaire. Women received this questionnaire, after they had signed up for a routine ultrasound examination offered freely to all pregnant women in weeks 17–18 of pregnancy. It included detailed questions about use of vitamins, minerals, and other dietary supplements in 4-wk time windows from before pregnancy. They were asked to record the use according to the ingredient list on the supplement container. Self-reported use of folic acid and other dietary supplements has been described previously in this cohort [18, 20, 21].

For the present analysis, we created six variables to examine timing of folic acid supplementation: (i) supplementation in weeks 13–17; (ii) supplementation in weeks 9–12; (iii) supplementation in weeks –4–8; (iv) initiation of supplementation: no folic acid; weeks –4–0; 0–4; 5–8; 9–12; 13–17; (v) supplementation in every 4-wk period from –4 to 17; (6) supplementation in every 4-wk period from –4 to 12. For the first three of these six variables, we differentiated supplement use into four mutually exclusive categories: (i) no use of dietary supplements; (ii) other supplements, but no folic acid; (iii) folic acid only; (iv) folic acid in combination with other supplements. For the other three of these six variables, we combined (i) and (ii) to represent “no folic acid supplementation,” and combined (iii) and (iv) to represent “folic acid supplementation.”

As shown in Table 1, potential confounders were maternal education (<12 years; 12 years, 13–16 years, 17+ years); maternal age (<25 years, 25–29 years, 30–34 years, 35+ years); planned pregnancy (no/yes); parity (0, 1, 2+); BMI (<25, 25–29, 30–34, 35+); smoking (no, sometimes, daily). Plasma folate values are presented as medians and interquartile ranges.

2.3 Laboratory measurements

Collection of biological samples and laboratory methods have been described previously [22]. Nonfasting blood samples were used for the preparation of plasma, collected into EDTA tubes, centrifuged within 30 min after collection, and placed in the hospital refrigerator (4°C). They were sent by ordinary postal service over-night to the Biobank of MoBa at the Norwegian Institute of Public Health. On the day of

Table 1. Maternal characteristics according to maternal use of supplements in weeks 13–17 of pregnancy and median folate in plasma from week 18 (25th and 75th percentile in parenthesis), $N = 2911$

	No supplements		Other supplements		Folic acid only		Folic acid plus		Plasma folate		p values
	n	%	n	%	n	%	n	%	nmol/L	Percentiles 25th/75th	
Maternal education											
<12	334	(29.8)	127	(20.0)	42	(19.9)	159	(16.8)	7.1	(5.1–11.5)	<0.000 ^{a)}
12	196	(17.5)	90	(14.2)	19	(9.0)	137	(14.5)	7.9	(5.2–12.9)	
13–16	405	(36.2)	264	(41.6)	97	(46.0)	418	(44.1)	9.3	(6.3–16.0)	
17+	148	(13.2)	132	(20.8)	45	(21.3)	215	(22.7)	10.4	(7.2–17.6)	
Missing	36	(3.2)	21	(3.3)	8	(3.8)	18	(1.9)	8.1	(5.8–12.3)	
Maternal age											
<25	168	(15.0)	83	(13.1)	19	(9.0)	95	(10.0)	6.7	(4.8–10.0)	<0.000 ^{a)}
25–29	403	(36.0)	206	(32.5)	75	(35.5)	311	(32.8)	8.2	(5.9–14.1)	
30–34	368	(32.9)	253	(39.9)	89	(42.2)	396	(41.8)	9.8	(6.4–16.3)	
35+	180	(16.1)	92	(14.5)	28	(13.3)	145	(15.3)	9.9	(6.1–16.4)	
Pregnancy planning											
No	260	(23.2)	125	(19.7)	32	(15.2)	185	(19.5)	7.7	(5.3–11.7)	<0.000 ^{a)}
Yes	838	(74.9)	496	(78.2)	177	(83.9)	747	(78.9)	9.1	(6.1–15.6)	
Missing	21	(1.9)	13	(2.1)	2	(0.9)	15	(1.6)	9.1	(6.4–16.0)	
Maternal BMI											
<25	680	(60.8)	435	(68.6)	141	(66.8)	652	(68.8)	9.2	(6.3–15.9)	<0.000 ^{a)}
25–29	239	(21.4)	133	(21.0)	42	(19.9)	172	(18.2)	8.0	(5.6–12.8)	
30–34	96	(8.6)	35	(5.5)	16	(7.6)	66	(7.0)	7.3	(5.0–12.2)	
35+	42	(3.8)	13	(2.1)	7	(3.3)	28	(3.0)	7.2	(5.0–12.0)	
Missing	62	(5.5)	18	(2.8)	5	(2.4)	29	(3.1)	7.6	(5.3–11.5)	
Parity											
0	395	(34.7)	285	(44.5)	87	(41.0)	457	(48.1)	9.8	(6.4–16.8)	<0.000 ^{a)}
1	448	(39.4)	232	(36.3)	88	(41.5)	330	(34.7)	8.6	(6.0–14.0)	
2+	294	(25.9)	123	(19.2)	37	(17.5)	163	(17.2)	7.6	(5.2–12.7)	
Maternal smoking											
No	923	(82.5)	557	(87.9)	195	(92.4)	836	(88.3)	9.1	(6.1–15.5)	<0.000 ^{a)}
Sometimes	52	(4.6)	29	(4.6)	4	(1.9)	39	(4.1)	7.4	(5.0–13.1)	
Daily	127	(11.3)	43	(6.8)	12	(5.7)	65	(6.9)	6.5	(4.3–9.8)	
Missing	17	(1.5)	5	(0.8)	0	(0.0)	7	(0.7)	7.3	(5.5–13.7)	

a) Kruskal–Wallis test used for differences in plasma medians.

receipt (usually 1–2 days after blood collection), EDTA plasma samples were aliquoted onto polypropylene microtiter plates (300 μ L in each well, 96-well format), sealed with heat-sealing foil sheets, and stored in a freezer at -80°C . Plasma folate was determined by microbiological assay, using a chloramphenicol resistant strain of *Lactobacillus casei* [23]. The assay determines biologically active folate species, predominantly 5-methyl-tetrahydrofolate, and has a CV that corresponds to 4% within-day and 5% between days, at a population median. The sample handling did not involve addition of ascorbic acid.

2.4 Statistical analysis

To compute p values for differences in plasma folate medians, we used the Kruskal–Wallis test. To describe the relationship between supplement use (no supplements; other supplements; folic acid only; folic acid plus) in the three windows of exposure (weeks 13–17; 9–12; –4–8) we used Spearman's

rank correlation. To examine the relationship of self-reported supplement use within three specified time periods (weeks 13–17; 9–12; –4–8) to plasma folate at week 18, we used unadjusted and adjusted linear regression models with plasma folate as a continuous outcome. The predictor variables were dummy variables created from the four categories of supplement use (no supplement; other supplement; folic acid only; folic acid plus) within each of these three time periods of exposure. The nonstandardized regression coefficient (B) shows the expected difference in nanomole per liter plasma folate for the different exposure categories (type of supplement used) with no supplement use as the reference category. We further examined the relationship of folic acid use according to when folic acid was started (weeks –4–0; 0–4; 5–8; 9–12; 13–17) to plasma folate at week 18. Predictor variables were dummy variables created for folic acid use (no/yes) within each of the 4-wk windows, with no folic acid use as the reference category. We also examined the relationship of continuous folic acid use (from weeks –4 to 17) to plasma folate at week 18. Since some women used folic acid before conception but

Table 2. Number and percentage of maternal supplement use in the different periods of use (weeks 13–17; 9–12; –4–8). Supplement use categorized as no supplements; other supplements; folic acid only; and folic acid plus, $N = 2911$

Supplement use in weeks	No supplements		Other supplements		Folic acid only		Folic acid plus	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
13–17	1 119	38.4	634	21.8	211	7.2	947	32.5
9–12	1 223	42.0	234	8.0	512	17.6	942	32.4
–4–8	1 180	40.5	267	9.2	526	18.1	938	32.2

stopped folic acid after week 12, we also examined continuous use through week 12. All statistical analyses were performed using SPSS version 17.0 (SPSS Inc, Chicago, IL, USA). All *p* values were two sided and values below 0.05 were considered statistically significant.

3 Results

The mean age of the pregnant women was 30 years, more than 40% had 13–16 years of education, more than 40% were pregnant with their first child, 77% said the pregnancy was planned, 65% had a BMI less than 25 kg/m², and about 12% reported smoking (Table 1).

The relationship between maternal report of supplement use and maternal plasma folate, respectively, with covariates (maternal age, BMI, education, pregnancy planning, parity, and smoking) are presented in Table 1. All the covariates showed some association with either supplement use or plasma levels, or both.

Table 2 describes the patterns of reported folate supplementation for three time periods (weeks 13–17; 9–12; –4–8). The use of "folic acid only" was higher (17–18%) for weeks –4–8 and weeks 9–12 than for weeks 13–17 (7.2%). Cessation of folic acid supplements after week 12 would be in accord with official Norwegian guidelines. By contrast, use of "folic acid in combination with other supplements" was similar (32%) in all three periods.

Correlations between the three periods (weeks 13–17; 9–12; –4–8) of supplement use (no supplements; other supplements; folic acid only; folic acid plus) are presented in Table 3 and ranged from 0.39 to 0.66 (all significant at $p < 0.001$).

Table 3. Spearman correlations between the three periods of supplement use: weeks 13–17; 9–12; –4–8 (supplement use in four categories: no supplements; other supplements; folic acid only; folic acid plus), $N = 2911$

Weeks	Weeks 13–17	Weeks 9–12	Weeks –4–8
13–17	1		
9–12	0.459**	1	
–4–8	0.395**	0.660**	1

** $p < 0.001$.

In Table 4, plasma folate is shown for the six different combinations of timing and type of supplement reported. Median plasma folate at week 18 (in nmol/L) was 5.67 for 844 (28.9%) reporting no use of folic acid; 15.72 for 238 (11.5%) reporting continuous use from –4 wk to 17 wk; and 13.34 for 1158 (39.7%) reporting use in weeks 13–17. The highest folate levels are seen in women who reported use of folic acid in weeks 13–17 (combinations 1, 4, and 5 in Table 4). Women that reported continuous use through week 17 had about threefold higher median plasma folate than women reporting no folic acid use at all in the same period.

Table 5 presents the relation between plasma folate and patterns of reported supplement use in three models, based on linear regression, for three different periods, with "no supplement use" as the reference in each. Model 1 is unadjusted; model 2 adjusted for all the covariates in Table 1; and model 3 is further adjusted by including the use of supplements in the other two periods. The nonstandardized regression coefficient (B) shows the expected difference in nanomole per liter plasma folate for the different exposure categories (type of supplement used). In model 3, reported use of folic acid only and folic acid plus in weeks 13–17 shows a strong relationship with plasma folate levels in week 18. The same relationship is not evident for report of use in weeks 9–12 and weeks –4–8. This lack of association would be expected for two reasons related to the change in pattern of supplement use. First, 50% of women report to use folic acid in weeks 9–12, while in weeks 13–17 the proportion of use is down to 40% (Table 2). Those women who discontinue the use after week 12 are mainly the women that used folic acid only. Second, as can be seen under (4) in Table 4 several women, that reported no use of folic acid in weeks –4–8, started to use folic acid in weeks 9–17.

When analyzing the relationship according to start of folic acid use and plasma folate levels, weeks 13–17 again showed the strongest association. Continuous use of folic acid from weeks –4 to 17 showed a stronger association than continuous use that was discontinued by week 12 (Table 6).

4 Discussion

There were three main findings. First, we found intriguing differences in the patterns of use among those who reported using folic acid only, and those using folic acid in

Table 4. Mean and median plasma folate (nmol/L) in week 18 for the different patterns of maternal report of supplement use, $n = 2911$

	<i>N</i>	Mean	Median	Percentiles 25th/75th
(1) Use of supplements anytime in weeks 13–17				
No supplements	1 119	8.49	6.77	(4.89–9.79)
Other supplements only	634	9.41	7.96	(5.86–10.95)
Folic acid only	211	16.04	12.89	(8.06–21.43)
Folic acid plus	947	15.92	13.80	(8.63–21.72)
(2) Use of supplements anytime in weeks 9–12				
No supplements	1 223	9.97	7.08	(4.90–11.57)
Other supplements only	234	9.99	7.08	(5.16–12.35)
Folic acid only	512	11.32	8.99	(6.81–12.71)
Folic acid plus	942	14.43	11.77	(7.90–19.03)
(3) Use of supplements anytime in weeks –4 to 8				
No supplements	1 180	9.25	6.84	(4.79–10.79)
Other supplements only	267	12.02	8.21	(5.36–14.83)
Folic acid only	526	12.22	9.51	(6.86–14.66)
Folic acid plus	938	14.25	11.41	(7.89–18.95)
(4) Initiation of folic acid week –4–17				
No folic acid	844	6.96	5.67	(4.29–7.66)
Start weeks –4–0	500	13.99	11.06	(7.77–18.93)
Start weeks 0–4	413	13.55	10.80	(7.46–17.73)
Start weeks 5–8	551	13.08	10.23	(7.33–16.49)
Start weeks 9–12	301	11.49	9.37	(6.79–14.27)
Start weeks 13–17	302	15.87	13.23	(7.69–21.22)
(5) Use of folic acid in every 4 week period –4–17	238	17.17	15.72	(9.37–23.10)
(6) Use of folic acid in every 4 week period –4–12	351	14.86	12.32	(8.28–20.17)

combination with other supplements. About 18% of the women used “folic acid only” in the period from before pregnancy to 12 wk of gestation, but after week 12, about 60% of these stopped taking folic acid. They were most likely following the official Norwegian guidelines, i.e. they used a folic acid supplement of 400 µg and stopped after the third month

of pregnancy. For those women who reported folic acid use in combination with other supplements, the proportion did not change; about 32% took supplements in all three windows of exposure. This group probably contains women who only used a multivitamin, as well as those who used other vitamins or supplements with various amounts of folic acid.

Table 5. Crude and adjusted linear coefficients for maternal report of supplement use and plasma levels of folate, no supplement use as reference, $N = 2911$

	<i>N</i>	Model 1			Model 2 ^{a)}			Model 3 ^{b)}		
		B	95% CI		B	95% CI		B	95% CI	
Weeks 13–17										
Other supplements only	634	0.922	0.14	1.69	0.335	–0.45	1.12	–.246	–1.08	0.59
Folic acid only	211	7.549	6.37	8.71	6.879	5.69	8.06	6.744	5.52	7.96
Folic acid plus	947	7.425	6.73	8.11	6.657	5.94	7.36	5.580	4.76	6.39
Weeks 9–12										
Other supplements only	234	0.015	–1.16	1.10	–0.115	–1.30	1.07	–1.209	–2.43	0.01
Folic acid only	512	1.348	0.47	2.22	0.805	–0.08	1.69	–0.405	–1.34	0.53
Folic acid plus	942	4.459	3.74	5.17	3.686	2.93	4.43	0.238	–0.77	1.24
Weeks –4–8										
Other supplements only	267	2.772	1.65	3.89	2.491	1.36	3.61	2.309	1.15	3.45
Folic acid only	526	2.975	2.11	3.84	2.406	1.52	3.28	1.556	0.62	2.48
Folic acid plus	938	5.006	4.28	5.72	4.294	3.54	5.03	2.291	1.33	3.25

Supplement use patterns are included as dummies. Linear regression was used to determine the coefficients for folate plasma levels (subjects with no supplement use in the relevant period as reference, $B = 0$). Missing was excluded pairwise.

a) Adjusted for education, age, planned pregnancy, BMI, and smoking.

b) Adjusted for education, age, planned pregnancy, BMI, smoking, and the other windows of supplement use (weeks 9–12 and –4–8; 13–17 and –4–8; 13–17 and 9–12).

Table 6. Crude and adjusted linear coefficients for maternal report of folic acid use and plasma levels of folate, $N = 2911$

	<i>N</i>	Model 1			Model 2 ^{a)}		
		B	95% CI		B	95% CI	
Folic acid (no/yes)							
Start weeks 4–0	500	7.032	6.13	7.51	6.038	5.09	6.98
Start weeks 0–4	413	6.589	5.63	7.92	5.820	4.83	6.80
Start weeks 5–8	551	6.123	5.25	7.54	5.495	4.59	6.39
Start weeks 9–12	301	4.525	3.46	6.99	3.845	2.74	4.93
Start weeks 13–17	302	8.906	7.84	9.97	8.013	6.91	9.10
Folic acid in every 4 week period							
Weeks –4–17	238	6.005	4.87	7.13	5.104	3.95	6.24
Folic acid in every 4 week period							
Weeks –4–12	351	3.647	2.68	4.60	2.760	1.78	3.73

Folic acid use dichotomized. Linear regression was used to determine the coefficients for folate plasma levels (subjects with no folic acid supplement use as reference, $B = 0$).

a) Adjusted for education, age, planned pregnancy, BMI, and smoking.

Second, maternal report of timing and length of folic acid supplements was well reflected in maternal folate plasma levels in week 18. Plasma folate levels in week 18 were most strongly associated with the maternal report of folic acid use in weeks 13–17. Women who reported the use of folic acid in this period had higher plasma folate than women with no use of folic acid in the same period, regardless of whether a folic acid supplement had been used earlier in pregnancy. A small group of women reported continuous use of folic acid supplements from before pregnancy to week 17. These women had the highest plasma folate levels, likely reflecting that plasma folate is a function of accumulative folate intake. We did, however, observe that women who followed the official guidelines, to use folic acid from before pregnancy through the second or third month of pregnancy (but not after week 12), had lower plasma folate levels than women who reported folic acid use in weeks 13–17 only.

Third, we found no association between plasma folate levels in week 18 and maternal report of folic acid use during the period from before pregnancy to 8 wk of gestation, absent continued use continued use of folate after week 8. We suggest two main reasons for this finding. One is that, as noted above, some women took folic acid supplements in accord with official Norwegian guidelines, i.e. stopped taking folic acid supplements at week 12. The lower levels in this group may reflect the natural progression of pregnancy (increasing plasma volume and increasing utilization of available folate), which could lead to depleted folate levels between folic acid discontinuation (week 12) and blood sampling (week 18) [24, 25]. The other is that some of the women, who did not take folic acid supplements during the period before pregnancy to 8 wk of gestation, started taking folic acid after week 8. This would increase their plasma folate levels at week 18, especially because of the strong influence of recent intake.

To our knowledge, this is the first prospective study where pregnant women responded to detailed questions regarding supplement use over 4-wk periods, referring to ingredients lists on the supplement containers. The precision of these data made it possible to differentiate patterns of maternal report of supplement use with plasma folate levels in week 18 (also the median week for return of the questionnaire). The detailed data collection also made it possible to create four mutually exclusive categories of supplement use, and thereby separate women who used folic acid only from women who used folic acid together with other micronutrients. Strengths of our study include its prospective design, detailed assessment of supplement use, careful measurement of plasma folate in week 18, and detailed information about important covariates.

A potential weakness is that recall may be better for more recent supplement use. Another limitation is that we had no information on the dose of folic acid taken. We also acknowledge that the use of nonfasting plasma samples might have added preanalytical variation, potentially attenuating the associations. It should be noted that the optimal folic acid dose has not been established. Official guidelines for periconceptional supplement use and food fortification with folate, vary among countries. For example, the official guideline in the US recommends a higher daily intake (400–800 μg) [26], although the recommended time period for use is similar to Norway (from 1 month before conception through the first trimester). Also, by contrast with Norway, the US has a policy of food supplementation with folate. These and other differences (e.g. dietary patterns) need to be taken into account when considering the implications of these findings for studies in other countries. Finally, while this paper has focused primarily on periconceptional use of folic acid, it should be kept in mind that the use of folic acid may be beneficial throughout pregnancy and lactation. For example, folic acid use later in pregnancy has been associated in some studies with reduced risk

of preterm birth and low-birth babies [27, 28]. In a previous publication from the MoBa cohort, however, we did not find maternal folate status in the second trimester to be associated with either birth weight or gestational age [18].

In conclusion, our results suggest that self-reported folic acid use had a strong and coherent relationship with plasma folate at week 18. But self-reported use from before pregnancy to 8 wk of gestation was not associated with plasma folate at week 18, absent continued use after week 8. For periconceptional supplementation per se, self-report may offer a better measure than plasma folate at week 18.

The Norwegian Mother and Child Cohort Study is supported by the Norwegian Ministry of Health, NIH/NIEHS (grant No. N01-ES-85433), NIH/NINDS (grant No.1 U01 NS 047537–01), and the Norwegian Research Council/FUGE (grant No. 151918/S10). Ezra Susser was supported in part by a NARSAD distinguished investigator award. Christine Roth was supported by the Norwegian Research Council (grant No. 181847/V50) and by a travel grant from the American Women's Club of Oslo.

The authors have declared no conflict of interest.

5 References

- [1] Zeisel, S. H., Importance of methyl donors during reproduction. *Am. J. Clin. Nutr.* 2009, *89*, 673S–677S.
- [2] Iskandar, B. J., Rizk, E., Meier, B., Hariharan, N. et al., Folate regulation of axonal regeneration in the rodent central nervous system through DNA methylation. *J. Clin. Invest.* 2010, *120*, 1603–1616.
- [3] Czeizel, A. E., Dudas, I., Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. *N. Engl. J. Med.* 1992, *327*, 1832–1835.
- [4] Werler, M. M., Shapiro, S., Mitchell, A. A., Periconceptional folic acid exposure and risk of occurrent neural tube defects. *JAMA* 1993, *269*, 1257–1261.
- [5] Daly, L. E., Kirke, P. N., Molloy, A., Weir, D. G., Scott, J. M., Folate levels and neural tube defects. Implications for prevention. *JAMA* 1995, *274*, 1698–1702.
- [6] Shaw, G. M., Schaffer, D., Velie, E. M., Morland, K., Harris, J. A., Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. *Epidemiology* 1995, *6*, 219–226.
- [7] Berry, R. J., Li, Z., Erickson, J. D., Li, S. et al., Prevention of neural-tube defects with folic acid in China. China-US Collaborative Project for Neural Tube Defect Prevention. *N. Engl. J. Med.* 1999, *341*, 1485–1490.
- [8] Milunsky, A., Jick, H., Jick, S. S., Bruell, C. L. et al., Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. *JAMA* 1989, *262*, 2847–2852.
- [9] MRC Vitamin Study Research Group, Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. *Lancet* 1991, *338*, 131–137.
- [10] Daltveit, A. K., Vollset, S. E., Lande, B., Oien, H., Changes in knowledge and attitudes of folate, and use of dietary supplements among women of reproductive age in Norway 1998–2000. *Scand. J. Public Health* 2004, *32*, 264–271.
- [11] Committee on Genetics, Folic acid for the prevention of neural tube defects. *Am. Acad. Pediatr.* 1999, *104*, 325–327.
- [12] Roth, C., Magnus, P., Schjøberg, S., Stoltenberg, C. et al., Folic acid supplements in pregnancy and severe language delay in children. *JAMA* 2011, *306*, 1566–1573.
- [13] Hertz-Picciotto, I., Pastore, L. M., Beaumont, J. J., Timing and patterns of exposures during pregnancy and their implications for study methods. *Am. J. Epidemiol.* 1996, *143*, 597–607.
- [14] Chatzi, L., Plana, E., Daraki, V., Karakosta, P. et al., Metabolic syndrome in early pregnancy and risk of preterm birth. *Am. J. Epidemiol.* 2009, *170*, 829–836.
- [15] Gracie, S. K., Lyon, A. W., Kehler, H. L., Pennell, C. E. et al., All our babies cohort study: recruitment of a cohort to predict women at risk of preterm birth through the examination of gene expression profiles and the environment. *BMC Pregnancy Childbirth* 2010, *10*, 87.
- [16] Qiu, C., Williams, M. A., Vadachkoria, S., Frederick, I. O., Luthy, D. A., Increased maternal plasma leptin in early pregnancy and risk of gestational diabetes mellitus. *Obstet. Gynecol.* 2004, *103*, 519–525.
- [17] Magnus, P., Irgens, L. M., Haug, K., Nystad, W. et al., MoBa Study Group, Cohort profile: the Norwegian Mother and Child Cohort Study (MoBa). *Int. J. Epidemiol.* 2006, *35*, 1146–1150.
- [18] Nilsen, R. M., Vollset, S. E., Monsen, A. L., Ulvik, A. et al., Infant birth size is not associated with maternal intake and status of folate during the second trimester in Norwegian pregnant women. *J. Nutr.* 2010, *140*, 572–579.
- [19] Baril, L., Carmel, R., Comparison of radioassay and microbiological assay for serum folate, with clinical assessment of discrepant results. *Clin. Chem.* 1978, *24*, 2192–2196.
- [20] Nilsen, R. M., Vollset, S. E., Gjessing, H. K., Magnus, P., Meltzer, H. M., Haugen, M., Ueland, P. M., Patterns and predictors of folic acid supplement use among pregnant women: the Norwegian Mother and Child Cohort Study. *Am. J. Clin. Nutr.* 2006, *84*, 1134–1141.
- [21] Haugen, M., Brantsaeter, A. L., Alexander, J., Meltzer, H. M., Dietary supplements contribute substantially to the total nutrient intake in pregnant Norwegian women. *Ann. Nutr. Metab.* 2008, *52*, 272–280.
- [22] Rønningen, K. S., Paltiel, L., Meltzer, H. M., Nordhagen, R. et al., The biobank of the Norwegian Mother and Child Cohort Study: a resource for the next 100 years. *Eur. J. Epidemiol.* 2006, *21*, 619–625.
- [23] O'Broin, S., Kelleher, B., Microbiological assay on microtitre plates of folate in serum and red cells. *J. Clin. Pathol.* 1992, *45*, 344–347.
- [24] Letsky, E. A., Erythropoiesis in pregnancy. *J. Perinat. Med.* 1995, *23*, 39–45.

- [25] Milman, N., Byg, K. E., Hvas, A. M., Bergholt, T., Eriksen, L., Erythrocyte folate, plasma folate and plasma homocysteine during normal pregnancy and postpartum: a longitudinal study comprising 404 Danish women. *Eur. J. Haematol.* 2006, 76, 200–205.
- [26] Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. *Ann. Intern. Med.* 2009, 150, 626–631.
- [27] Czeizel, A. E., Puho, E. H., Langmar, Z., Acs, N., Banhidy, F., Possible association of folic acid supplementation during pregnancy with reduction of preterm birth: a population-based study. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2010, 148, 135–140.
- [28] Bukowski, R., Malone, F. D., Porter, F. T., Nyberg, D. A. et al., Preconceptional folate supplementation and the risk of spontaneous preterm birth: a cohort study. *PLoS Med.* 2009, 6, e1000061.